Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
- Conditions
- Chronic Lower Back PainChronic Pain
- Interventions
- Other: Placebo
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 1053
- Registration Number
- NCT02946073
- Locations
- 🇺🇸
Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸Boyett Health Services Inc, Hamilton, Alabama, United States
🇺🇸National Centers for Pain Management and Research, Vestavia Hills, Alabama, United States
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
- Conditions
- Schizophrenia
- Interventions
- Radiation: [18F]Fallypride Imaging
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02824666
- Locations
- 🇺🇸
Indiana Clinical Research Center, IU Health University Hospital, Indianapolis, Indiana, United States
Safety and Tolerability of Risperidone Implants
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT02773576
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Garden Grove, California, United States
Phase II Pharmacokinetics Study of CAM2038
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT02710526
- Locations
- 🇺🇸
Parkway Medical, Birmingham, Alabama, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸The Rivus Wellness & Research Institute, Oklahoma City, Oklahoma, United States
Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
- Conditions
- Opioid Use Disorder
- Interventions
- Drug: CAM2038 q1w or q4w exposure to SL BPN/NXDrug: CAM2038 q1w or q4w new to BPN treatment
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 228
- Registration Number
- NCT02672111
- Locations
- 🇺🇸
Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸Haleyville Clinical Research LLC, Haleyville, Alabama, United States
🇺🇸Boyett Health Services Inc, Hamilton, Alabama, United States
- Prev
- 1
- 2
- Next